New ALS drug
(`Motor Neuron Disease` or `MND` also known as `Lou Gehrig's disease`)
You can edit text on your website by double clicking on a text box on your website. Alternatively, when you select a 
A previously unknown problem protein has been discovered
A specifically designed new ALS drug, RCH4, successfully suppresses it
 ​RCH4 is available free of charge on compassionate basis depending on availability and location


Random ALS ALSFRS-R score charts

Demonstrating the variability of patient response 

ALS is a very heterogenious condition (i.e., it varies greatly) and indeed there may in fact be different types of the same condition. There is no definition of particular types or sub-types. That is not fully understood.
Emanating from this, therefore it is most unlikely that any single drug or treatment will be effective for all patients. 
Further, there are other diseases which can present the same (symptoms appear the same as ALS), so there is the possibility of an incorrect diagnosis in some cases. If the diagnosis is incorrect, then efficacy is being demonstrated in some other neurodegenerative disease.
There is a further complication in that PALS can respond very differently to any one treatment. Some 16% of patients do not respond. Their decline rate does not change after starting treatment, i.e., the drug does not work for them. Those cases can be seen in the charts below.

                                          The charts below are ramdom examples of the variations in response to treatment for ALS.
(Source: Patients own monthly monitoring reports ​n=629  p=0.0001)
End of life and the cause cited on the death certificates are noted where applicable. If no comment noted on the last datum point, treatment is ongoing.
      The average data for the whole treated population appears in the chart below (including non-responders):
 Comparison between RCH4 and Radicava (`Edaravone`) is shown in the chart below:
Molecule